
Iovance's revenue jumps 77% but lung cancer trial results drag stock down 48%
Iovance Biotherapeutics reported a strong quarter with Amtagvi revenue up 77% to $101.6 million and nearly halted cash burn at -$4.47 million. However, disappointing lung cancer trial results caused the stock to drop 47.6% since October 28, as the re...

